BioSpace News Archive

Drug Development

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathy

EyePoint Pharmaceuticals, Inc. today announced that the first patient has been dosed in the Phase 2 PAVIA clinical trial of EYP-1901.

September 29, 2022
·
6 min read
Biotech Bay

Lucira Health Reports Pilot Study Interim Results for Chlamydia and Gonorrhea Assays

Lucira Health, Inc. announced interim results of a pilot study to evaluate the performance of their combined Chlamydia trachomatis and Neisseria gonorrhoeae assays integrated into the instrument-free at-home Lucira molecular test platform.

September 29, 2022
·
7 min read
Drug Development

C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers

C4 Therapeutics, Inc. today announced it has received a Study May Proceed Letter from the United States Food and Drug Administration (FDA) to begin a Phase 1/2 trial for CFT1946, an orally bioavailable mutant-selective BiDAC™ degrader for the treatment of BRAF-V600 mutant solid tumors.

September 29, 2022
·
5 min read
Business

Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates

Pluri Inc. today issued the following update to shareholders from Chief Executive Officer and President Yaky Yanay announcing that it had signed its second technology collaboration agreement centered on Pluri’s 3D cell expansion platform and providing some financial status updates.

September 29, 2022
·
9 min read
Drug Development

OncoNano Medicine Announces Positive Phase 2 Data for Pegsitacianine as an adjunct to Cytoreductive Surgery of Peritoneal Carcinomatosis

OncoNano Medicine, Inc. today announced positive interim clinical results from an ongoing Phase 2 study of its lead clinical development candidate, pegsitacianine.

September 29, 2022
·
4 min read
Drug Development

Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia

Silence Therapeutics plc today announced preliminary results from the single dose component of the GEMINI II phase 1 study of SLN124.

September 29, 2022
·
5 min read
Genetown

Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting

Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting.

September 29, 2022
·
7 min read
NuGen M.D. to File for Patent Protection in the United States, Europe and China

NuGen Medical Devices Inc. is pleased to announce that it intends to file for a new patent in the United States, Europe and China.

September 29, 2022
·
3 min read
Drug Development

Excision BioTherapeutics Awarded California Institute for Regenerative Medicine (CIRM) Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV

Excision BioTherapeutics, Inc. today announced that the California Institute for Regenerative Medicine (CIRM) has awarded Excision a $6.85 million grant to support the clinical development of the EBT-101 program for human immunodeficiency virus type 1 (HIV-1).

September 29, 2022
·
4 min read
Pharm Country

Cognition Therapeutics to Participate in the 2022 Cantor Fitzgerald Neurology & Psychiatry Conference

Cognition Therapeutics, Inc. announced today that the Company’s president and CEO, Lisa Ricciardi will participate in a panel discussion and host one-on-one meetings at the Cantor Fitzgerald Neurology & Psychiatry Conference taking place in San Francisco from October 6-7, 2022.

September 29, 2022
·
4 min read